These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 23322214)

  • 21. Optimizing efficacy of mucosal vaccines.
    Gebril A; Alsaadi M; Acevedo R; Mullen AB; Ferro VA
    Expert Rev Vaccines; 2012 Sep; 11(9):1139-55. PubMed ID: 23151169
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of mucosal immunity through systemic immunization: Phantom or reality?
    Su F; Patel GB; Hu S; Chen W
    Hum Vaccin Immunother; 2016 Apr; 12(4):1070-9. PubMed ID: 26752023
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mucosal vaccination and therapy with genetically modified lactic acid bacteria.
    Wells J
    Annu Rev Food Sci Technol; 2011; 2():423-45. PubMed ID: 22129390
    [TBL] [Abstract][Full Text] [Related]  

  • 24. B cell and T cell immunity in the female genital tract: potential of distinct mucosal routes of vaccination and role of tissue-associated dendritic cells and natural killer cells.
    Anjuère F; Bekri S; Bihl F; Braud VM; Cuburu N; Czerkinsky C; Hervouet C; Luci C
    Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():117-22. PubMed ID: 22882377
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mucosal delivery of fish vaccines: Local and systemic immunity following mucosal immunisations.
    Somamoto T; Nakanishi T
    Fish Shellfish Immunol; 2020 Apr; 99():199-207. PubMed ID: 31911291
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IL-7-Adjuvanted Vaginal Vaccine Elicits Strong Mucosal Immune Responses in Non-Human Primates.
    Logerot S; Figueiredo-Morgado S; Charmeteau-de-Muylder B; Sandouk A; Drillet-Dangeard AS; Bomsel M; Bourgault-Villada I; Couëdel-Courteille A; Cheynier R; Rancez M
    Front Immunol; 2021; 12():614115. PubMed ID: 33717097
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of Lactobacillus gasseri as a candidate oral vaccine vector.
    Stoeker L; Nordone S; Gunderson S; Zhang L; Kajikawa A; LaVoy A; Miller M; Klaenhammer TR; Dean GA
    Clin Vaccine Immunol; 2011 Nov; 18(11):1834-44. PubMed ID: 21900526
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adenovirus-vectored drug-vaccine duo as a potential driver for conferring mass protection against infectious diseases.
    Zhang J; Tarbet EB; Toro H; Tang DC
    Expert Rev Vaccines; 2011 Nov; 10(11):1539-52. PubMed ID: 22043954
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Defending the mucosa: adjuvant and carrier formulations for mucosal immunity.
    Lawson LB; Norton EB; Clements JD
    Curr Opin Immunol; 2011 Jun; 23(3):414-20. PubMed ID: 21511452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modes of Action for Mucosal Vaccine Adjuvants.
    Aoshi T
    Viral Immunol; 2017; 30(6):463-470. PubMed ID: 28436755
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Upper respiratory tract immunity.
    Zuercher AW
    Viral Immunol; 2003; 16(3):279-89. PubMed ID: 14583144
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [New routes of administration: epidermal, transcutaneous mucosal ways of vaccination].
    Denis F; Alain S; Ploy MC
    Med Sci (Paris); 2007 Apr; 23(4):379-85. PubMed ID: 17433227
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Delivery strategies to enhance oral vaccination against enteric infections.
    Davitt CJ; Lavelle EC
    Adv Drug Deliv Rev; 2015 Aug; 91():52-69. PubMed ID: 25817337
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Strategies for mucosal vaccine development.
    Boyaka PN; Marinaro M; Vancott JL; Takahashi I; Fujihashi K; Yamamoto M; van Ginkel FW; Jackson RJ; Kiyono H; McGhee JR
    Am J Trop Med Hyg; 1999 Apr; 60(4 Suppl):35-45. PubMed ID: 10344675
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Delivery systems: a vaccine strategy for overcoming mucosal tolerance?
    Mann JF; Acevedo R; Campo JD; Pérez O; Ferro VA
    Expert Rev Vaccines; 2009 Jan; 8(1):103-12. PubMed ID: 19093777
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mucosal immunity: implications for vaccine development.
    Holmgren J; Czerkinsky C; Lycke N; Svennerholm AM
    Immunobiology; 1992 Feb; 184(2-3):157-79. PubMed ID: 1587541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polymeric penetration enhancers promote humoral immune responses to mucosal vaccines.
    Klein K; Mann JF; Rogers P; Shattock RJ
    J Control Release; 2014 Jun; 183():43-50. PubMed ID: 24657807
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant lactobacillus expressing G protein of spring viremia of carp virus (SVCV) combined with ORF81 protein of koi herpesvirus (KHV): A promising way to induce protective immunity against SVCV and KHV infection in cyprinid fish via oral vaccination.
    Cui LC; Guan XT; Liu ZM; Tian CY; Xu YG
    Vaccine; 2015 Jun; 33(27):3092-9. PubMed ID: 25981489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New insights in mucosal vaccine development.
    Pavot V; Rochereau N; Genin C; Verrier B; Paul S
    Vaccine; 2012 Jan; 30(2):142-54. PubMed ID: 22085556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New advances in mucosal vaccination.
    Ranasinghe C
    Immunol Lett; 2014 Oct; 161(2):204-6. PubMed ID: 24462961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.